Health Care Equipment

Medprin

Medprin released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 78.36 M, actual EPS CNY 0.31

Medprin released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 119.6 M, actual EPS CNY 0.5469

Medprin released FY2025 annual earnings on April 27 After-Market (BJT), actual revenue CNY 368.83 M (forecast CNY 382.1 M), actual EPS CNY 1.69 (forecast CNY 1.6)

Medprin to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

Medprin to Release FY2025 Earnings on April 28 After-Market (BJT), Forecast Revenue CNY 382.1 M, EPS CNY 1.6

Medprin released FY2025 Q3 earnings on October 23 After-Market BJT, actual revenue CNY 91.45 M, actual EPS CNY 0.4301

Medprin released FY2025 9 Months Earnings on October 23 After-Market BJT, actual revenue CNY 249.23 M, actual EPS CNY 1.1307

Medprin FY2025 Q3 Earnings Release on October 24, 2025, After-Market (BJT)

Medprin released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 84.07 M, actual EPS CNY 0.3405

Medprin released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 157.78 M, actual EPS CNY 0.71

Medprin to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Maplemed Maintains B Rating in ESG Assessment

Fund Managers Adjust Positions in Healthcare and Defense Sectors

Tang Ying Plans to Reduce Shares in Mapmed

Maple Medical Accepts Institutional Research

Maple Medical's stock rises and receives multiple buy ratings

Mepro Medical Actively Developing Dura Sealants and Hemostatic Particles

Guoshou Chengda plans to reduce holdings in Maypro Medical by 3%

Maple Medical Explains Its Product Involvement in Brain-Computer Interface

Mindray Medical's Neurosurgery Products Market Penetration Rate Increases

301033

Medprin announced that shareholder Tang Ying reduced her holdings in the company by 665,100 shares through centralized bidding transactions from July 30, 2025, to October 27, 2025, at an average reduction price of 77.49 yuan/share, accounting for 0.9920% of the company's total share capital. Before the reduction, Tang Ying held 1.506 million shares, accounting for 2.2640%; after the reduction, she held 840,900 shares, accounting for 1.2541%. Together with the concerted actor Ye Tao, they held a total of 2.3109 million shares, accounting for 3.4465%

Zhitong

Medprin: Tang Ying has reduced her holdings by 0.9920%

Medprin released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 249 million yuan, a year-on-year increase of 30.53%; net profit attributable to the parent company was 75.854 million yuan, a year-on-year increase of 43.65%; net profit excluding non-recurring gains and losses was 72.7919 million yuan, a year-on-year increase of 57.94%; basic earnings per share were 1.15 yuan

Medprin released its performance for the first three quarters, with a net profit attributable to the parent company of 75.854 million yuan, an increase of 43.65%

Medprin announced that the company intends to issue shares and pay cash to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. at a transaction price of 335 million yuan. At the same time, the company plans to raise supporting funds of 134 million yuan from Guangzhou Yijian Medical Investment Co., Ltd., issuing a total of 2.3291 million shares at a price of 57.35 yuan per share

Medprin: Plans to issue shares and pay cash to acquire assets and raise supporting funds of 134 million yuan

Guangzhou Medprin Regenerative Medicine Technology Co., Ltd. disclosed the progress of its acquisition of 100% equity in Guangzhou Yijie Medical Technology Co., Ltd. This transaction is expected not to constitute a major asset reorganization but is classified as a related party transaction. Planning for the transaction began on May 22, 2025, and after a suspension and resumption of trading, due diligence is still ongoing, and related work has not yet been completed. The transaction requires approval from the board of directors, shareholders' meeting, and review by the Shenzhen Stock Exchange and the China Securities Regulatory Commission, which introduces uncertainty. The company will update progress in a timely manner

Medprin disclosed the progress of the equity transaction for acquiring Yijie Medical, with uncertainties still remaining

According to the Zhitong Finance APP, Medprin announced that its research and development project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules" has recently officially entered the clinical trial stage. In surgical procedures, when ligation or other traditional hemostatic methods cannot be performed or are ineffective, this product can be used as an auxiliary hemostatic product to control capillary, venous, and small arterial bleeding

Medprin: Absorbable regenerated oxidized cellulose hemostatic granules enter clinical trial phase

Medprin announced that the company plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through the issuance of shares and cash payment, and to raise matching funds. This transaction is expected not to constitute a major asset reorganization, but it will constitute a related party transaction and will not constitute a restructuring listing. Currently, the company is cooperating with various intermediary institutions to carry out due diligence, auditing, and evaluation, and the relevant work has not yet been completed. Once the relevant work is completed, the company will hold another board meeting to review the formal plan for this transaction and submit it to the company's shareholders' meeting for consideration

Medprin: Plans to issue shares and pay cash to acquire assets and raise supporting funds

Medprin released its semi-annual report for 2025, with operating revenue of 158 million yuan, a year-on-year increase of 29.28%. The net profit attributable to the parent company was 47.2991 million yuan, a year-on-year increase of 46.03%; the net profit excluding non-recurring gains and losses was 45.9964 million yuan, a year-on-year increase of 66.20%. The basic earnings per share were 0.71 yuan

Medprin released its performance for the first half of the year, with a net profit attributable to the parent company of 47.2991 million yuan, an increase of 46.03%

603706

36Kr learned that the three major A-share indices collectively rose during the midday break, with the Shanghai Composite Index up 0.51%, the Shenzhen Component Index up 0.34%, and the ChiNext Index up 0.91%; the gas, computer hardware, and healthcare sectors led the gains, with Dongfang Huanyu hitting the daily limit, Medprin rising over 12%, and Xiechuang Data rising over 10%; the aerospace and military, chemical fiber, and biotechnology sectors saw the largest declines, with Jieqiang Equipment and Kexing Pharmaceutical falling over 6%, and Haizheng Biomaterials dropping over 2%

36Kr

Xinjiang East Universe Gas

The three major A-share indices closed collectively higher at midday, with Xinjiang East Universe Gas hitting the daily limit

300595

The concept of innovative drugs continues to be active, driving the medical device sector to catch up. AUTEK hit a 20% limit up, Medprin rose over 10%, and companies like Baipusais, Aibo Medical, Tailin Biotech, Zhend Medical, and Kaili Medical also saw gains

AUTEK

The medical device sector rises, AUTEK hits the 20% limit up

688298

In the first half of 2025, the portfolio adjustments of several well-known fund managers were revealed, mainly focusing on the medical and military sectors. Wan Minyuan from Rongtong Fund reduced his holdings in Orient Biotech in the first quarter and increased them in the second quarter; the China Europe Medical Health Mixed Fund managed by Grantham has newly included Medprin among its top ten circulating shareholders. Wu Xingwu from GF Fund reduced his holdings, while Chen Yunzhong increased his holdings in military stocks

Orient Biotech

Famous fund manager's portfolio adjustment revealed, intensively participating in the medical and military sectors

Medprin(301033.SZ)